Revela completed the final phase of an NIH contract for the non-invasive detection of human CD8+ T cells: A PET-based approach to assess the human immune system. Current methods to predict responses to immunotherapy are inadequate. Revela has shown that tracking the short-term infiltration of CD8+ T cells into a tumor can predict longer-term responses to immunotherapy, and therefore has the potential to help clinicians more accurately tailor treatment plans. The overall goal of this contract was the successful preclinical development of a product for in vivo tracking of intratumoral human CD8+ T cells using PET imaging. A panel of novel VHHs targeting human CD8 protein have been developed and are entering late-stage preclinical development over the coming year..

For more, see the Revela website.